Vertex Pharmaceuticals (NQ:VRTX)

504.73 -2.01 (-0.40%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9

...

77 78 Next >

Forget Centessa Pharmaceuticals: This Rare‑Disease Specialist Has a Superior Portfolio and Pipeline ↗

February 26, 2026

One of these is not like the other.

Via The Motley Fool

Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics

February 25, 2026

In a definitive move to dominate the next frontier of immunology and oncology, Eli Lilly and Company (NYSE: LLY) announced on February 9, 2026, its acquisition of Orna Therapeutics for a total...

Via MarketMinute

Topics Intellectual Property

2 Nasdaq 100 Stocks Worth Your Attention and 1 We Question

February 24, 2026

The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a winner - some are struggling with slowing...

Via StockStory

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Posts Mixed Q4 2025 Results, Provides 2026 Guidance ↗

February 12, 2026

Via Chartmill

The Ultimate Biotech Stock to Buy With $500 Right Now ↗

February 24, 2026

This biotech powerhouse could maintain its strength for the long term.

Via The Motley Fool

Topics Intellectual Property

Could Vertex Stock Help Turn $100,000 Into $1 Million by 2036? ↗

February 22, 2026

Even a great stock has a ceiling.

Via The Motley Fool

Topics Intellectual Property

The Gene‑Therapy Breakthrough Story You'll Be Mad You Ignored at These Prices ↗

February 20, 2026

Forget Vertex Pharmaceuticals -- CRISPR Therapeutics is a better buy right now.

Via The Motley Fool

Topics ETFs

CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows ↗

February 19, 2026

Via MarketBeat

5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q4 Earnings Call

February 19, 2026

Vertex Pharmaceuticals delivered fourth quarter results that outpaced Wall Street's revenue expectations, driven by continued expansion in cystic fibrosis therapies and early contributions from...

Via StockStory

Topics Earnings

1 S&P 500 Stock with Competitive Advantages and 2 We Turn Down

February 18, 2026

The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some...

Via StockStory

Topics Stocks

Vertex: The Quiet Biotech Compounder I'd Happily Hold Through Any Market Crash ↗

February 18, 2026

Vertex has the revenue power to excel during any market environment.

Via The Motley Fool

Topics Artificial Intelligence Intellectual Property

Vertex to Participate in TD Cowen 46th Annual Health Care Conference on March 3

February 17, 2026

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Moderna’s mRNA Renaissance: Navigating Volatility and the Post-Pandemic Pipeline

February 17, 2026

As of February 17, 2026, Moderna, Inc. (NASDAQ:MRNA) finds itself at a pivotal crossroads in its corporate evolution. Long defined by its meteoric rise during the COVID-19 pandemic, the Cambridge-based...

Via Finterra

Topics Economy Intellectual Property

Sanofi Tightens Grip on Ocular Therapeutix with Revised Bid as Pivotal SOL-1 Trial Results Loom

February 16, 2026

In a move that could reshape the multi-billion-dollar retinal disease market, French pharmaceutical giant Sanofi (NASDAQ: SNY) has reportedly returned to the negotiating table with a significantly...

Via MarketMinute

Moderna, Vertex Pharmaceuticals, Integra LifeSciences, Baxter, and Molina Healthcare Shares Are Soaring, What You Need To Know

February 13, 2026

A number of stocks jumped in the afternoon session after a softer-than-expected inflation report fueled hopes for interest rate cuts by the Federal Reserve. The January Consumer Price Index (CPI), a...

Via StockStory

Topics Economy

The Blastoff-Ready Biotech Stock You'll Kick Yourself for Not Buying in 2026 ↗

February 13, 2026

2026 could be a big year for this company.

Via The Motley Fool

Top S&P500 movers in Friday's session ↗

February 13, 2026

Via Chartmill

Why CRISPR Therapeutics Stock Is Up Today (Despite Its Q4 Earnings Miss) ↗

February 13, 2026

A sales partner offered a ray of hope that this company couldn't for itself.

Via The Motley Fool

Friday's session: top gainers and losers in the S&P500 index ↗

February 13, 2026

Via Chartmill

Gilead Sciences and the 2026 Biotech Resurgence: A Leader in the Great Rotation

February 13, 2026

As of February 13, 2026, the financial markets are witnessing a historic "Great Rotation," where institutional capital is flowing out of overextended technology valuations and into the defensive,...

Via MarketMinute

Topics Artificial Intelligence ETFs Government

VRTX Q4 Deep Dive: Diversification Beyond Cystic Fibrosis Sets Stage for Next Growth Phase

February 13, 2026

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, with sales up 9.5% year on year to $3.19 billion. The company expects the full...

Via StockStory

Vertex (VRTX) Q4 2025 Earnings Call Transcript ↗

February 12, 2026

Vertex (VRTX) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Vertex Pharmaceuticals’s (NASDAQ:VRTX) Q4 CY2025: Beats On Revenue

February 12, 2026

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q4 CY2025 results topping the market’s revenue expectations, with sales up 9.5% year on year to $3.19 billion. The company expects the full...

Via StockStory

Vertex Reports Fourth Quarter and Full Year 2025 Financial Results

February 12, 2026

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex Pharmaceuticals (VRTX) Q4 Earnings: What To Expect

February 10, 2026

Via StockStory

Topics Artificial Intelligence World Trade

1 Reason I'd Buy Vertex Pharmaceuticals Stock and Never Sell ↗

February 10, 2026

Vertex stock has climbed more than 60% over three years.

Via The Motley Fool

Topics Intellectual Property

Should You Buy Vertex Before Feb. 12? ↗

February 10, 2026

Biotech Vertex, known for its cystic fibrosis therapies, is set to report earnings on Feb. 12

Via The Motley Fool

Topics Intellectual Property

Provident Dumps 490,000 MapleBear Shares Worth $18 Million ↗

February 09, 2026

Maplebear Inc. connects North American households with personal shoppers through its technology-driven grocery delivery platform.

Via The Motley Fool

Topics Regulatory Compliance

Should You Buy Vertex Pharmaceuticals Before Feb. 12? ↗

February 09, 2026

The next 12 months will be important for the drugmaker.

Via The Motley Fool

The Bond Market Is Flashing a Clear Warning About the Fed: 3 Stocks to Buy ↗

February 08, 2026

The bond market is speaking more loudly than the stock market about the likely direction of the Federal Reserve.

Via The Motley Fool

Topics Bonds Economy Government

< Previous 1 2 3 4 5 6 7 8 9

...

77 78 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.